Why the study?
Are novel oral anticoagulants (rivaroxaban, dabigatran, apixaban) effective for thromboprophylaxis in patients undergoing elective major orthopedic surgery?
Are novel oral anticoagulants (rivaroxaban, dabigatran, apixaban) effective for thromboprophylaxis in patients undergoing elective major orthopedic surgery?
NOACs (rivaroxaban, dabigatran, apixaban) are effective alternatives to traditional anticoagulants for VTE prophylaxis following major orthopedic surgery.
No takes yet. Share an insight, caveat, or question.
Supports NOAC thromboprophylaxis after arthroplasty; confirms RCT efficacy but leaves real-world adoption open.
Rachidi et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: